Study Summary
This trial will study the effects of a cancer treatment combining chemotherapy, immunotherapy, and electric fields on lung cancer.
- Non-Small Cell Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: Surgical resection
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Aliya PEF ablation
1 of 1
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: Aliya PEF ablation · No Placebo Group · Phase 4
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
- Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6. Review.
- Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6.
- 2023. "Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05583188.
Frequently Asked Questions
Is Aliya PEF ablation hazardous for people's health?
"Aliya PEF ablation has been approved and is thus rated a 3 on the 1-3 scale of safety." - Anonymous Online Contributor
Are researchers currently seeking more participants for this trial?
"According to records from clinicaltrials.gov, this research project is no longer recruiting candidates - the initial post was made on November 1st of 2022 and it has since been duly updated as recently as October 24th of 2022. However, there are currently 1529 other trials that are still enrolling patients for participation." - Anonymous Online Contributor